FcIgG receptor-bearing lymphocytes and monoclonal antibody-defined T cell subsets in atopic dermatitis: effect of treatment with thymopoietin pentapeptide (TP-5)

Int Arch Allergy Appl Immunol. 1982;69(3):238-44. doi: 10.1159/000233177.

Abstract

Lymphocyte subpopulations were determined in the blood of patients with atopic dermatitis (AD) before and after treatment with the thymopoietin pentapeptide TP-5. The relative and absolute numbers of lymphocytes bearing suppressor/cytotoxic cell markers (FcIgG+E+ and T8+ cells) were significantly decreased in the untreated patients and the T4+/T8+ cell ratio was increased, indicating an imbalance between lymphocyte subpopulations in AD. Patients who had been treated for 6 weeks with TP-5 displayed no significant abnormality of any of the lymphocyte subsets studied and comparison of pre- and posttreatment values revealed that there was a statistically significant increase in T8+ cell numbers, that by contrast did not take place in placebo-treated AD patients. The treatment had no demonstrable effect on IgE serum levels or on the spontaneous in vitro production of IgE by cultured lymphocytes from the patients.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Monoclonal*
  • Clinical Trials as Topic
  • Dermatitis, Atopic / drug therapy*
  • Dermatitis, Atopic / immunology
  • Humans
  • Immunoglobulin E / biosynthesis
  • Lymphocytes / cytology
  • Peptide Fragments / therapeutic use*
  • Receptors, Fc / analysis*
  • T-Lymphocytes / classification
  • Thymopentin
  • Thymopoietins / therapeutic use*
  • Thymus Hormones / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Peptide Fragments
  • Receptors, Fc
  • Thymopoietins
  • Thymus Hormones
  • Immunoglobulin E
  • Thymopentin